Skip to main content

Table 3 Analysis of time to first CID by selected eosinophil cut-offs (pooled analysis; full study duration)

From: Reduced risk of clinically important deteriorations by ICS in COPD is eosinophil dependent: a pooled post-hoc analysis

Cut-off, ×109/L (% ≤)Lower stratumUpper stratum
BUD/FORM 160/4.5 μg bidFORM
4.5 μg bid
HR (95% CI)BUD/FORM 160/4.5 μg bidFORM
4.5 μg bid
HR (95% CI)
0.10 (25.2)201/285 (70.5)199/291 (68.4)0.97 (0.80–1.18)569/857 (66.4)633/853 (74.2)0.67 (0.60–0.75)
0.15 (44.8)350/503 (69.6)373/520 (71.7)0.82 (0.71–0.95)420/639 (65.7)459/624 (73.6)0.68 (0.59–0.77)
0.20 (60.9)466/675 (69.0)519/718 (72.3)0.78 (0.69–0.88)304/467 (65.1)313/426 (73.5)0.69 (0.59–0.80)
0.25 (73.1)560/818 (68.5)613/852 (71.9)0.78 (0.69–0.87)210/324 (64.8)219/292 (75.0)0.64 (0.53–0.78)
0.30 (79.9)616/896 (68.8)670/931 (72.0)0.79 (0.71–0.88)154/246 (62.6)162/213 (76.1)0.57 (0.46–0.71)
0.35 (85.2)659/965 (68.3)708/983 (72.0)0.77 (0.69–0.86)111/177 (62.7)124/161 (77.0)0.58 (0.45–0.75)
  1. Numbers shown: event/total (%)
  2. bid, twice daily; BUD Budesonide, CID Clinically Important Deterioration, CI Confidence interval, FORM Formoterol, HR Hazard ratio